Co-Diagnostics Inc. Class Action Lawsuit The Co-Diagnostics class action lawsuit seeks to represent purchasers of Co-Diagnostics, Inc. (NASDAQ: CODX) publicly traded securities between May 12, 2022 and the close of the market on August 11, 2022 (4:00 p.m. ET), inclusive (the “Class Period”). The Co-Diagnostics class action lawsuit – captioned Stadium Capital LLC v. Co-Diagnostics, Inc., No. 22-cv-06978 (S.D.N.Y.) – charges Co-Diagnostics and certain of its top executive officers with violations of the Securities Exchange Act of 1934. If you suffered losses in Co-Diagnostics stock and wish to serve as lead plaintiff of the Co-Diagnostics class action lawsuit, please provide your information below. You can also contact Co-Diagnostics Stock Loss Lawyer Timothy L. Miles by calling 855/846-6529 or via e-mail at tmiles@timmileslaw.com. Lead plaintiff motions for the Co-Diagnostics class action lawsuit must be filed with the court no later than October 17, 2022. If you suffered losses in Co-Diagnostics stock and have questions, please contact Co-Diagnostics Stock Loss Lawyer Timothy L. Miles today. https://www.classactionlawyertn.com/co-diagnostics-inc.html #covid #shareholders #investing #investorsformula @Investment Joy @The Shareholders @Bloomberg Markets and Finance @Yahoo Finance https://www.pinterest.com/tmiles676767/ https://www.facebook.com/timmileslaw/ https://www.linkedin.com/in/timothy-l-miles-79a69a32/ https://www.instagram.com/10k_law/ https://www.youtube.com/channel/UCbEh7RkQ94C6KVlZGubIYmQ
from
https://www.youtube.com/watch?v=n5giHO3I-kA
Subscribe to:
Post Comments (Atom)
AUTODESK CLASS ACTION LAWSUIT
The Autodesk class action lawsuit seeks to represent purchasers or acquirers of Autodesk, Inc. (NASDAQ: ADSK) publicly traded securities bet...
-
JUUL ADDICTION LAWSUIT from https://www.youtube.com/watch?v=hDwYmVVvxJE
-
Top Workers Compensation Attorney Nashville from https://www.youtube.com/watch?v=rbSDfQqLZdo
-
NASHVILLE OZEMPIC LAWYER LAW OFFICES OF TIMOTHY L. MILES (855) 846-6529 | tmiles@timmileslaw.com WHAT ABOUT OZEMPIC AND PANCREATITIS? FROM A...
No comments:
Post a Comment